

## **Preliminary Questionnaire**

The purpose of the Preliminary Questionnaire is to assist the REB and the Qualification Team in preparing for the on-site review process. Please complete and sign the Preliminary Questionnaire and email it to CTO at **qualification@ctontario.ca** along with the documents requested.

Please complete form by either checking the appropriate box and/or providing responses as applicable. Attach additional sheets as necessary.				
SECTION 1 - General Information				
a) Name of Institution	(b) Name of Research Ethics Board (REB) A separate questionnaire should be completed for each REB			
c) Does the REB have any subcommittees or panels?	,			
Yes No				
If yes, please provide the purpose and focus of review	v for each subcommittee or panel:			
d) Please describe any affiliated institutions or external sites for which the REB is a Board of Record:				
e) Are there formal agreements covering the Board of Record arrangements with each of the affiliated institutions or external sites?				
Yes No				



f) Is there an Annual Report available either electronically or in hard copy?			
Yes No			
If yes, please provide a hard copy or the link to an online version:			
SECTION 2 - REB Standard Operating Procedures			
a) Please select one of the following options to submit your REB Standard Operating Procedures (SOPs) to CTO:			
Option 1: Copy of REB SOPs enclosed			
Option 2: REB SOPs are publicly available. Please provide website link:			
b) Are any SOPs under revision or currently being developed and have not been submitted?			
Yes No			
If yes, please list the titles of these SOPs and the expected completion date:			
SECTION 3 - REB Governance			
a) Please describe the formal reporting relationship of the REB to the home institution:			
b) Please describe the formal reporting relationship of the REB Office, and personnel within the office, to the REB/institution:			

Clinical Trials Ontario	661 University Avenue, Suite 460 MaRS Centre, West Tower Toronto, Ontario M5G 1M1 Canada www.ctontario.ca
<ul> <li>c) If available, please provide an organizational chart(s) depict REB and the REB office.</li> <li>Enclosed Not Available</li> </ul>	ing the reporting relationships of the
SECTION 4 - REB Membership a) Please select one of the following options to submit your RE qualifications, gender, citizenship and areas of expertise an REB) to CTO. If the REB has subcommittees or panels please well.	d role(s) each member serves on the
Option 1: Copy of REB membership enclosed	vide website link:
b) Are any changes expected to the REB membership in the ne	ear future?
Yes No	
If yes, please describe:	
SECTION 5 - REB Office/Administrative Support	
<ul> <li>a) Please provide a list of individuals working with the REB (e.g roles and responsibilities:</li> </ul>	g., REB Operations Personnel), their



SECTION 6 - Research Reviewed by the REB		
a) Please estimate how man	y reviews the REB conducts annually in each of the categories:	
Initial Reviews	Continuing Reviews/ Renewals	
Amendments	Reportable Events (unanticipated problems, deviations, etc.)	
b) How many studies (total)	are currently approved and require ongoing review by the REB?	
(i) How many of these are	e clinical trials?	
(ii) How many of these ar	e multi-centre clinical trials?	
<ul> <li>c) Please provide a brief des epidemiologic studies, et</li> </ul>	cription of the types of studies reviewed by the REB (e.g. clinical trials, c.):	
d) Please indicate how ofter	n your REB meets:	
d) Are the meeting dates an	d deadline dates for REB submissions publically posted?	
	a deadine dates for REB submissions publicany posted:	
Yes No		
If yes, please provide website link:		



e) Please provide a brief description of any metrics collected by the REB (e.g., time from meeting to letter issuance, etc.):
SECTION 7 - REB Records
a) Are REB records (minutes, correspondence, etc.) available for inspection?
Yes No
b) Please indicate where and how REB records are stored. If records are stored electronically, please provide website link:
c) Please describe measures to protect the privacy and confidentiality of the records:



d) Please provide the following documents as part of the Qualification package:	
<ol> <li>REB Application forms (Initial submission, Amendments, Continuing Review, Unanticipated Problems):</li> </ol>	
Option 1: Enclosed	
Option 2: Publicly available. Please provide website link:	
2. Informed Consent form templates	
Option 1: Enclosed	
Option 2: Publicly available. Please provide website link:	



SECTION 8 - REB Compliance Inspections					
	as the REB been inspected by a regulatory ag	gency such as t	the Food and	Drug Admini	stration
v	/ithin the last 5 years?				
	Yes No				
If Yes	S.				
	When was the inspection?	Type of in	spection		ort available
	(YYYY/MM/DD)	Routine	For Cause	for	review?
1	S			Yes	No
2				Yes	No
3				Yes	No
b) D	oes the REB hold an accreditation?				
	Yes No				
If Ye	S:				
(i)	Name of the accreditation:				
(ii)	(ii) Accreditation Expiration Date:				
SECT	ION 9 - Regulatory Compliance				
	lease indicate what regulations, policies, etc. omplies with on a voluntary basis.	your REB is ei	ther required	l to comply w	vith or
	<u>Compliance?</u>				
	Canadian Food and Drugs Act and applic Regulations	cable	Yes	No	
	US Code of Federal Regulations		Yes	No	
	ICH GCP		Yes	No	
	PHIPA and Ontario Regulation 329/04		Yes	No	
	Tri-Council Policy Statement (TCPS 2) Other (Please specify):		Yes	No	



SECTION 10 – Institution	al Contacts			
a) Please provide the name of the institutional contact(s) for the REB (such as the Vice-President, Research), for the institution hosting the REB and institution(s) the REB serves:				
Contact Name	Contact Role	Contact Email	Institution Name	
SECTION 11 - Review Foo	cus			
please describe: This form has been comp	of compliance you would li	ke the reviewers to pay pa	rticular attention to,	
Print Name:		Signature:		
		Signatule.		
Title:		Date:		